Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.439
Buy
RSI(14)
71.947
Buy
STOCH(KDJ)(9,3,3)
88.498
Overbought
ATR(14)
2.676
High Vlolatility
CCI(14)
144.559
Buy
Williams %R
10.443
Overbought
TRIX(12,20)
0.717
Sell
StochRSI(14)
71.806
Sell
Search
LB Pharmaceuticals Inc
LBRXAdd to Watchlist
40.080USD
-0.820-2.00%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.15BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.00%
5 Days
+14.48%
1 Month
+19.89%
6 Months
+74.95%
Year to Date
+80.05%
1 Year
0.00%
Key Figures
40.390Open
40.670High
339.02KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.34%Turnover Ratio
40.900Prev. Close
38.975Low
11.41MTurnover
LossP/E Static
3.37P/B
0.00%Div Yield TTM
--ROA
33.47052wk High
0.82Volume Ratio
-63.10MNet Profit
25.30MShares
-1.4345EPS TTM
--Beta
--ROE
13.36052wk Low
4.14%Amplitude
--Gross Margin
1.15BMarket Cap
5.69Reward/Risk
3.94%Risk Rate
LB Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
45.778
Target Price
+14.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
LB Pharmaceuticals Inc
LBRX
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
37.940
Buy
MA10
35.838
Buy
MA20
34.269
Buy
MA50
31.322
Buy
MA100
29.609
Buy
MA200
24.786
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
LB Pharmaceuticals Inc Info
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Ticker SymbolLBRX
CompanyLB Pharmaceuticals Inc
CEOTurner (Heather D)
Websitehttps://lbpharma.us/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52790.700
+412.700 (+0.79%)
28511.600
+350.700 (+1.25%)
7535.400
+60.300 (+0.81%)
14618.000
-131.000 (-0.89%)
63608.000
+756.000 (+1.20%)
6405.900
+40.500 (+0.64%)
78.472
-7.462 (-8.68%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4058.760
+17.330 (+0.43%)
FAQs
What is the current price of LB Pharmaceuticals Inc (LBRX)?
The current price of LB Pharmaceuticals Inc (LBRX) is 40.08.
What is the symbol of LB Pharmaceuticals Inc?
The ticker symbol of LB Pharmaceuticals Inc is LBRX.
What is the 52-week high of LB Pharmaceuticals Inc?
The 52-week high of LB Pharmaceuticals Inc is 33.47.
What is the 52-week low of LB Pharmaceuticals Inc?
The 52-week low of LB Pharmaceuticals Inc is 13.36.
What is the market capitalization of LB Pharmaceuticals Inc?
The market capitalization of LB Pharmaceuticals Inc is 1.15B.
Is LB Pharmaceuticals Inc (LBRX) currently rated as Buy, Hold, or Sell?
According to analysts, LB Pharmaceuticals Inc (LBRX) has an overall rating of Buy, with a price target of 45.78.
What is the Earnings Per Share (EPS TTM) of LB Pharmaceuticals Inc (LBRX)?
The Earnings Per Share (EPS TTM) of LB Pharmaceuticals Inc (LBRX) is -1.00.